Hana Přikrylová Vranová1, Eva Hényková2, Jan Mareš3, Michaela Kaiserová3, Kateřina Menšíková3, Miroslav Vaštík3, Petr Hluštík3, Jana Zapletalová4, Miroslav Strnad2, David Stejskal5, Petr Kaňovský3. 1. Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic. Electronic address: vranovaha@seznam.cz. 2. Laboratory of Growth Regulators, Palacky University, Olomouc, Czech Republic. 3. Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic. 4. Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. 5. Department of Biochemistry, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Abstract
INTRODUCTION: Clusterin, a heterodimeric glycoprotein, is thought to be involved in many cellular functions, including cell-cell interaction, cell survival and apoptosis. In the brain, post-mortem analysis has found increased clusterin associated with the pathology of many other neurodegenerative diseases (ND) such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD) and multiple system atrophy (MSA). In vivo cerebrospinal fluid (CSF) levels of clusterin in ND diseases may reflect differences in the pathology and thus aid in the differential diagnosis. METHODS: CSF levels of clusterin were assessed in 102 patients with clinical manifestations of neurodegenerative diseases (23 patients with PD, 18 with PDD, 15 with DLB, 18 with AD, 16 with PSP, 12 with MSA) and 21 subjects as a control group (CG). RESULTS: Significantly higher CSF clusterin levels were found in PD compared to CG (median 6884 vs. 4484; p=0.012), DLB (median 6884 vs. 4192; p=0.023), MSA (median 6884 vs. 3606; p=0.001) and PSP (median 6884 vs. 4193; p=0.014). Significantly higher CSF clusterin levels were found in PDD compared to CG (median 8617 vs. 4484; p=0.045), DLB (median 8617 vs. 4192; p=0.025) and MSA (median 8617 vs. 3606; p=0.004). CONCLUSION: The results of the presented "feasibility" study support the role of clusterin in PD/PDD pathogenesis. Clusterin CSF levels could serve as a potential marker for PDD and DLB differentiation.
INTRODUCTION: Clusterin, a heterodimeric glycoprotein, is thought to be involved in many cellular functions, including cell-cell interaction, cell survival and apoptosis. In the brain, post-mortem analysis has found increased clusterin associated with the pathology of many other neurodegenerative diseases (ND) such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD) and multiple system atrophy (MSA). In vivo cerebrospinal fluid (CSF) levels of clusterin in ND diseases may reflect differences in the pathology and thus aid in the differential diagnosis. METHODS: CSF levels of clusterin were assessed in 102 patients with clinical manifestations of neurodegenerative diseases (23 patients with PD, 18 with PDD, 15 with DLB, 18 with AD, 16 with PSP, 12 with MSA) and 21 subjects as a control group (CG). RESULTS: Significantly higher CSF clusterin levels were found in PD compared to CG (median 6884 vs. 4484; p=0.012), DLB (median 6884 vs. 4192; p=0.023), MSA (median 6884 vs. 3606; p=0.001) and PSP (median 6884 vs. 4193; p=0.014). Significantly higher CSF clusterin levels were found in PDD compared to CG (median 8617 vs. 4484; p=0.045), DLB (median 8617 vs. 4192; p=0.025) and MSA (median 8617 vs. 3606; p=0.004). CONCLUSION: The results of the presented "feasibility" study support the role of clusterin in PD/PDD pathogenesis. Clusterin CSF levels could serve as a potential marker for PDD and DLB differentiation.
Authors: Qinying Yu; Xiaofang Zhong; Bingming Chen; Yu Feng; Min Ma; Carol A Diamond; Julie S Voeller; Miriam Kim; Kenneth B DeSantes; Christian M Capitini; Neha J Patel; Margo L Hoover-Regan; Michael J Burke; Kimberly Janko; Diane M Puccetti; Chrysanthy Ikonomidou; Lingjun Li Journal: J Proteome Res Date: 2020-05-27 Impact factor: 4.466
Authors: J M Gregory; E Elliott; K McDade; T Bak; S Pal; S Chandran; S Abrahams; C Smith Journal: Neuropathol Appl Neurobiol Date: 2019-08-28 Impact factor: 8.090
Authors: Drahomira Holmannova; Pavel Borsky; Lenka Borska; Ctirad Andrys; Kvetoslava Hamakova; Vit Rehacek; Tereza Svadlakova; Andrea Malkova; Martin Beranek; Vladimir Palicka; Jan Krejsek; Zdenek Fiala Journal: Int J Mol Sci Date: 2020-08-05 Impact factor: 5.923